Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
However, in a large study involving people with diabetes who had no comorbidities, GLP-1 RAs were not shown to increase the risk of developing pancreatitis at any time point up through 5 years of use.[ref][ref][ref][ref] The Cleveland Clinic now counsels that GLP-1 RA patients should be screened for pancreatitis risk factors, and a lower dose should be used to reduce the risk of pancreatitis.[ref] Related article : Pancreatitis and Genetic Risk Factors Gastroparesis: Case reports tie semaglutide to a risk of gastroparesis (very slow stomach emptying)
Now, lets be clear: The same FDA-approved medications will have the same weight loss profile regardless of where you get them
References Batterham, R
PMID 29119245
Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity
